Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9102463 | 1.00 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL384008 | 1.00 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9943895 | 1.00 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15797176 | 1.00 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9100876 | 0.89 | KMT2A (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9100869 | 0.89 | KMT2A (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2546240 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL5468267 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL10270529 | 0.86 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9106760 | 0.86 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101588-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2289893-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2011-03-02 | — | — | EP | disclosed |
| US-7723340-B2 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | PHARMACOPEIA, LLC | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287344-A1 | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | TPMT, MGMT, HPRT1 | CTSK 4836/4885CTSS 4823/4885CA1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.